ArticleThoracic cancer2019
FLOT1 promotes tumor development, induces epithelial-mesenchymal transition, and modulates the cell cycle by regulating the Erk/Akt signaling pathway in lung adenocarcinoma.
Article in Thoracic cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- RETRACTION: FLOT1 promotes tumor development, induces epithelial-mesenchymal transition, and modulates the cell cycle by regulating the Erk/Akt signaling pathway in lung adenocarcinoma.Thoracic cancer · 2026Article
- Luteolin suppresses cell migration and invasion via targeting miR-6809-5p/FLOT1/FAK and eliciting EMT in hepatocellular carcinoma.Translational oncology · 2025Article
- Prognostic value of FLOT1-related gene signature in head and neck squamous cell carcinoma: insights into radioresistance mechanisms and clinical outcomes.Cell death discovery · 2025Article
- The Role of CENPK Splice Variant in Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.Cells · 2024Article
- Enhanced therapeutic potential of Flotillins-modified MenSCs by improve the survival, proliferation and migration.Molecular biology reports · 2024Article
- The expression characteristic and prognostic role of Siglec-15 in lung adenocarcinoma.The clinical respiratory journal · 2024Article
- The roles of FLOT1 in human diseases (Review).Molecular medicine reports · 2023Review
- EIF4A3 Acts on the PI3K-AKT-ERK1/2-P70S6K Pathway through FLOT1 to Influence the Development of Lung Adenocarcinoma.Molecular cancer research : MCR · 2023Article
- FLI1 and FRA1 transcription factors drive the transcriptional regulatory networks characterizing muscle invasive bladder cancer.Communications biology · 2023Article
- Article
- The Structural Proteins of Membrane Rafts, Caveolins and Flotillins, in Lung Cancer: More Than Just Scaffold Elements.International journal of medical sciences · 2023Review
- Review
- Silencing LINC01116 suppresses the development of lung adenocarcinoma via the AKT signaling pathway.Thoracic cancer · 2021Article
- CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.Oncology reports · 2021Article
- Upregulation of LINC01426 promotes the progression and stemness in lung adenocarcinoma by enhancing the level of SHH protein to activate the hedgehog pathway.Cell death & disease · 2021Article
- SKA3 promotes lung adenocarcinoma metastasis through the EGFR-PI3K-Akt axis.Bioscience reports · 2020Article
- Identification of an Immune-Related Gene Signature to Improve Prognosis Prediction in Colorectal Cancer Patients.Frontiers in genetics · 2020Article
- Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway.Molecules (Basel, Switzerland) · 2019Article
- Tanshinone IIA Reverses Oxaliplatin Resistance In Human Colorectal Cancer Via Inhibition Of ERK/Akt Signaling Pathway.OncoTargets and therapy · 2019Article
- MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition.OncoTargets and therapy · 2019Article
Corrections and comments
- Erratum issued
- Retracted
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFLOT1 is a scaffolding protein of lipid rafts that is believed to be involved in numerous cellular processes. However, few studies have explored the function of FLOT1 in the development of lung adenocarcinoma (LUAD) and the underlying mechanisms of FLOT1 activity.
methodsFLOT1 knockdown and overexpression models were constructed via lentivirus. Cell growth, invasion, migration, and apoptosis were detected to evaluate the role of FLOT1 in LUAD development. Epithelial-mesenchymal transition (EMT) and cell cycle regulatory markers were then examined. Finally, the influence of FLOT1 on the Erk/Akt signaling pathway was investigated.
resultsFLOT1 promoted cell growth, invasion, and migration and inhibited cell apoptosis. In addition, FLOT1 induced EMT and modulated the cell cycle by activating the Erk/Akt signaling pathway.
conclusionThe findings indicate a significant role of FLOT1 in LUAD development. Targeting FLOT1 may be a potential therapeutic strategy for LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.